Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
This is a study to test if a new drug called NMS-03597812 is safe and effective in treating a type of cancer called RRMM in adults who have tried other treatments that didn't work well or weren't an option for them. The study will also look at how the drug is processed in the body and how well it fights cancer.
This is a study to test if a new drug called NMS-03597812 is safe and effective in treating a type of cancer called RRMM in adults who have tried other treatments that didn't work well or weren't an option for them. The study will also look at how the drug is processed in the body and how well it fights cancer.
*Third Opinion AI Generated Synopsis
Trial Summary
This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NMS-03597812 in adult patients with RRMM who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable.
This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NMS-03597812 in adult patients with RRMM who have exhausted standard treatment options that are expected to provide meaningful clinical benefit or for whom standard therapy is considered unsuitable.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: